Welcome

Investor Relations

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Latest Investor Presentation Latest Earnings Presentation
(Updated September 9, 2021) (Updated November 4, 2021)
Stock Information
NASDAQNVAX
NASDAQNVAX
Recent News
Nov 24, 2021
Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission to the...

Nov 23, 2021
Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate...

Nov 18, 2021
Novavax Statement on Publication of Positive Results from First Study of Co-administered COVID-19 and Influenza Vaccines

Positive results from the first co-administration study of a SARS-CoV-2 vaccine candidate and an approved influenza vaccine have been published in The Lancet Respiratory Medicine. The previously...

View All Press Releases

Events
Evercore ISI’s 4th Annual HealthCONx Virtual Conference
Thursday, December 2, 2021
9:15am - 9:35am EST
Add to Calendar
Set Email Reminder
Novavax Third Quarter 2021 Financial Results
Thursday, November 4, 2021
4:30pm - 5:30pm EDT
Cantor Global Healthcare Conference 2021
Wednesday, September 29, 2021
8:40am - 9:10am EDT

View All Events